drugset

drugset / Trial / NCT00949078

Omalizumab in the Treatment of Peanut Allergy

NCT00949078 ↗

Phase 2 Completed 51 enrolled Johns Hopkins University National Institute of Allergy and Infectious Diseases (NIAID) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if treatment with omalizumab (Xolair, anti-IgE) can eliminate or reduce symptoms of peanut allergy.

Timeline

Start: 2009-07
Primary completion: 2011-08
Completion: 2011-08

Publications

Background Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR Jr; Avon Longitudinal Study of Parents and Children Study Team. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003 Mar 13;348(11):986-93. doi: 10.1056/NEJMoa022613. Epub 2003 Mar 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omalizumab	Monoclonal antibody	—	Subcutaneous

Indications